Fulgent Genetics Inc (FLGT)

Debt-to-equity ratio

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Long-term debt US$ in thousands 2,964 — — — 3,372 — — — — 5,947 5,899 — — — — — — — — —
Total stockholders’ equity US$ in thousands 1,136,100 1,258,700 1,259,760 1,264,450 1,266,680 1,277,050 1,304,760 1,306,130 1,158,750 1,036,780 912,729 801,566 569,387 186,955 87,043 81,372 82,777 54,526 51,142 49,961
Debt-to-equity ratio 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

December 31, 2023 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $2,964K ÷ $1,136,100K
= 0.00

The debt-to-equity ratio of Fulgent Genetics Inc has been consistently low over the past eight quarters, indicating a conservative capital structure with a minimal reliance on debt financing. The ratio remained at 0.00 in Q4 2023, Q3 2023, and Q2 2023, which suggests that the company has no debt obligations relative to its equity during these periods.

In Q1 2023, the debt-to-equity ratio slightly increased to 0.02, indicating a marginal increase in debt relative to equity. This trend was also observed in the previous quarters of Q4 2022, Q3 2022, Q2 2022, and Q1 2022, where the ratio consistently stood at 0.02.

Overall, the stable and low debt-to-equity ratio of Fulgent Genetics Inc reflects a prudent financial management approach that prioritizes equity financing and minimizes financial risk associated with high levels of debt. It suggests a strong financial position and the ability to fund operations and growth through internal resources rather than external borrowing.